Bolni Nagalo
Concepts (204)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Blood Donors | 11 | 2021 | 31 | 4.010 |
Why?
| Hepatitis B | 8 | 2023 | 23 | 2.170 |
Why?
| Oncolytic Virotherapy | 3 | 2022 | 16 | 1.730 |
Why?
| HIV Infections | 11 | 2021 | 354 | 1.620 |
Why?
| Hepatitis B Surface Antigens | 4 | 2018 | 9 | 1.550 |
Why?
| Syphilis | 7 | 2019 | 25 | 1.350 |
Why?
| Carcinoma, Hepatocellular | 4 | 2023 | 194 | 1.180 |
Why?
| Hepatitis C | 5 | 2021 | 77 | 1.160 |
Why?
| Blood Transfusion | 3 | 2021 | 121 | 1.160 |
Why?
| Liver Neoplasms | 4 | 2023 | 332 | 1.080 |
Why?
| Seroepidemiologic Studies | 10 | 2021 | 43 | 0.930 |
Why?
| Burkina Faso | 16 | 2023 | 16 | 0.910 |
Why?
| Vesicular Stomatitis | 1 | 2022 | 1 | 0.850 |
Why?
| Enzyme-Linked Immunosorbent Assay | 4 | 2018 | 245 | 0.770 |
Why?
| Biliary Tract Neoplasms | 4 | 2022 | 8 | 0.750 |
Why?
| HIV Antibodies | 1 | 2018 | 10 | 0.660 |
Why?
| Blood-Borne Pathogens | 1 | 2018 | 7 | 0.650 |
Why?
| HIV-1 | 4 | 2018 | 55 | 0.600 |
Why?
| Gabon | 4 | 2019 | 4 | 0.530 |
Why?
| Mass Screening | 1 | 2018 | 351 | 0.510 |
Why?
| Rural Population | 1 | 2018 | 535 | 0.470 |
Why?
| Young Adult | 11 | 2021 | 3936 | 0.460 |
Why?
| Skin Neoplasms | 3 | 2024 | 487 | 0.440 |
Why?
| HIV Seroprevalence | 2 | 2014 | 4 | 0.430 |
Why?
| Vesiculovirus | 2 | 2022 | 5 | 0.430 |
Why?
| Humans | 35 | 2024 | 49827 | 0.420 |
Why?
| Cholangiocarcinoma | 2 | 2022 | 27 | 0.400 |
Why?
| Bile Duct Neoplasms | 2 | 2022 | 30 | 0.400 |
Why?
| Adolescent | 10 | 2021 | 6340 | 0.390 |
Why?
| Antibodies, Viral | 1 | 2011 | 88 | 0.390 |
Why?
| Adult | 16 | 2021 | 13160 | 0.380 |
Why?
| Plasma | 1 | 2011 | 43 | 0.380 |
Why?
| Communicable Diseases | 1 | 2011 | 55 | 0.370 |
Why?
| Melanoma | 2 | 2024 | 284 | 0.330 |
Why?
| Prevalence | 6 | 2018 | 943 | 0.290 |
Why?
| Female | 17 | 2021 | 26329 | 0.280 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 987 | 0.280 |
Why?
| Middle Aged | 12 | 2020 | 11997 | 0.280 |
Why?
| Male | 14 | 2021 | 25093 | 0.270 |
Why?
| Sensitivity and Specificity | 2 | 2018 | 854 | 0.270 |
Why?
| Hepacivirus | 2 | 2018 | 103 | 0.260 |
Why?
| Cell Proliferation | 4 | 2024 | 1007 | 0.240 |
Why?
| Molecular Docking Simulation | 2 | 2023 | 73 | 0.240 |
Why?
| Monophenol Monooxygenase | 1 | 2023 | 5 | 0.230 |
Why?
| Cell Line, Tumor | 3 | 2024 | 1402 | 0.230 |
Why?
| Antineoplastic Agents | 2 | 2024 | 1172 | 0.230 |
Why?
| Incidence | 2 | 2021 | 1003 | 0.230 |
Why?
| Carcinoma, Pancreatic Ductal | 1 | 2024 | 30 | 0.230 |
Why?
| Anti-HIV Agents | 2 | 2014 | 42 | 0.230 |
Why?
| Drug Synergism | 2 | 2021 | 150 | 0.220 |
Why?
| Hepatitis B virus | 2 | 2023 | 27 | 0.220 |
Why?
| Psoriasis | 1 | 2023 | 30 | 0.210 |
Why?
| Vesicular stomatitis Indiana virus | 1 | 2022 | 2 | 0.210 |
Why?
| Dermatitis | 1 | 2023 | 36 | 0.210 |
Why?
| Animals | 6 | 2023 | 13150 | 0.210 |
Why?
| Antioxidants | 2 | 2023 | 248 | 0.200 |
Why?
| Students, Medical | 1 | 2023 | 159 | 0.190 |
Why?
| Treponema pallidum | 2 | 2018 | 10 | 0.190 |
Why?
| Flavonols | 1 | 2020 | 4 | 0.190 |
Why?
| Pancreatic Neoplasms | 1 | 2024 | 213 | 0.190 |
Why?
| Viral Proteins | 1 | 2022 | 155 | 0.190 |
Why?
| Risk Factors | 4 | 2020 | 3619 | 0.190 |
Why?
| Disease Models, Animal | 2 | 2023 | 1451 | 0.180 |
Why?
| Cymbopogon | 1 | 2020 | 1 | 0.180 |
Why?
| Oils, Volatile | 1 | 2020 | 12 | 0.180 |
Why?
| Immunotherapy | 2 | 2021 | 238 | 0.180 |
Why?
| Receptors, KIR | 1 | 2019 | 13 | 0.180 |
Why?
| Sequence Deletion | 1 | 2020 | 67 | 0.180 |
Why?
| Protein Kinase Inhibitors | 1 | 2021 | 202 | 0.180 |
Why?
| Mice | 4 | 2023 | 5720 | 0.170 |
Why?
| Plasma Membrane Calcium-Transporting ATPases | 1 | 2019 | 2 | 0.170 |
Why?
| Glutathione Transferase | 1 | 2020 | 174 | 0.170 |
Why?
| Retrospective Studies | 6 | 2022 | 6117 | 0.170 |
Why?
| Polymorphism, Genetic | 1 | 2020 | 181 | 0.170 |
Why?
| Virology | 1 | 2018 | 6 | 0.160 |
Why?
| HIV | 1 | 2018 | 24 | 0.160 |
Why?
| Anti-Inflammatory Agents | 1 | 2020 | 162 | 0.160 |
Why?
| Aged | 6 | 2022 | 9272 | 0.160 |
Why?
| Molecular Structure | 3 | 2024 | 297 | 0.150 |
Why?
| Immunotherapy, Adoptive | 1 | 2018 | 154 | 0.140 |
Why?
| Blood Pressure | 1 | 2019 | 514 | 0.140 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2019 | 485 | 0.140 |
Why?
| Odds Ratio | 1 | 2018 | 548 | 0.140 |
Why?
| T-Lymphocytes | 1 | 2018 | 338 | 0.130 |
Why?
| Cross-Sectional Studies | 2 | 2018 | 1541 | 0.130 |
Why?
| Polymerase Chain Reaction | 2 | 2014 | 455 | 0.130 |
Why?
| Cisplatin | 3 | 2022 | 278 | 0.130 |
Why?
| HIV-2 | 1 | 2014 | 1 | 0.130 |
Why?
| Hospitals, Military | 1 | 2014 | 7 | 0.130 |
Why?
| Time Factors | 2 | 2018 | 2912 | 0.120 |
Why?
| Drug Monitoring | 1 | 2014 | 77 | 0.120 |
Why?
| Syphilis Serodiagnosis | 1 | 2014 | 4 | 0.120 |
Why?
| Antibodies, Monoclonal | 1 | 2018 | 458 | 0.120 |
Why?
| RNA, Viral | 2 | 2014 | 125 | 0.120 |
Why?
| Peritonitis | 1 | 2014 | 27 | 0.120 |
Why?
| Community-Acquired Infections | 1 | 2014 | 38 | 0.120 |
Why?
| Immunocompromised Host | 1 | 2014 | 120 | 0.120 |
Why?
| Genotype | 3 | 2023 | 538 | 0.120 |
Why?
| Viremia | 1 | 2014 | 22 | 0.120 |
Why?
| Neoplasms | 1 | 2023 | 1233 | 0.110 |
Why?
| Genetic Predisposition to Disease | 3 | 2023 | 510 | 0.110 |
Why?
| Meningitis, Bacterial | 1 | 2013 | 6 | 0.110 |
Why?
| Infectious Disease Transmission, Vertical | 1 | 2012 | 15 | 0.110 |
Why?
| Rubella | 1 | 2012 | 4 | 0.110 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 34 | 0.110 |
Why?
| Toxoplasmosis | 1 | 2012 | 15 | 0.110 |
Why?
| Antibodies, Protozoan | 1 | 2012 | 12 | 0.110 |
Why?
| Gene Frequency | 2 | 2023 | 94 | 0.110 |
Why?
| Bacteria | 1 | 2014 | 223 | 0.100 |
Why?
| Case-Control Studies | 3 | 2020 | 1128 | 0.100 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 181 | 0.100 |
Why?
| Bile Ducts, Intrahepatic | 2 | 2022 | 16 | 0.100 |
Why?
| Pilot Projects | 2 | 2013 | 699 | 0.100 |
Why?
| Drug Screening Assays, Antitumor | 2 | 2024 | 136 | 0.100 |
Why?
| Apoptosis | 3 | 2024 | 1100 | 0.100 |
Why?
| TOR Serine-Threonine Kinases | 2 | 2023 | 77 | 0.100 |
Why?
| Pregnancy Complications, Infectious | 1 | 2012 | 73 | 0.100 |
Why?
| Structure-Activity Relationship | 2 | 2024 | 394 | 0.100 |
Why?
| Deoxycytidine | 2 | 2021 | 27 | 0.100 |
Why?
| Tumor Microenvironment | 2 | 2024 | 210 | 0.090 |
Why?
| Hospitals, Teaching | 1 | 2011 | 53 | 0.090 |
Why?
| Autophagy | 2 | 2023 | 168 | 0.090 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2021 | 210 | 0.090 |
Why?
| Programmed Cell Death 1 Receptor | 2 | 2021 | 38 | 0.090 |
Why?
| Tumor Cells, Cultured | 2 | 2020 | 465 | 0.090 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 595 | 0.090 |
Why?
| Prospective Studies | 2 | 2012 | 2344 | 0.080 |
Why?
| Anti-Bacterial Agents | 1 | 2014 | 743 | 0.080 |
Why?
| rho-Associated Kinases | 1 | 2024 | 20 | 0.060 |
Why?
| Hedgehog Proteins | 1 | 2024 | 33 | 0.060 |
Why?
| Blood Banks | 2 | 2014 | 18 | 0.060 |
Why?
| Azoles | 1 | 2023 | 28 | 0.060 |
Why?
| Immunomodulation | 1 | 2024 | 37 | 0.060 |
Why?
| HLA-DRB1 Chains | 1 | 2023 | 4 | 0.060 |
Why?
| Research | 1 | 2023 | 112 | 0.050 |
Why?
| HLA Antigens | 1 | 2023 | 51 | 0.050 |
Why?
| Interleukin-17 | 1 | 2023 | 36 | 0.050 |
Why?
| Pyrazoles | 1 | 2023 | 113 | 0.050 |
Why?
| Medical Oncology | 1 | 2023 | 96 | 0.050 |
Why?
| Computer Simulation | 1 | 2023 | 282 | 0.050 |
Why?
| Platinum | 1 | 2022 | 11 | 0.050 |
Why?
| Sirolimus | 1 | 2023 | 62 | 0.050 |
Why?
| Alleles | 1 | 2023 | 251 | 0.050 |
Why?
| Clone Cells | 1 | 2022 | 74 | 0.050 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 157 | 0.050 |
Why?
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 2 | 0.050 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 141 | 0.050 |
Why?
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 11 | 0.050 |
Why?
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2021 | 11 | 0.050 |
Why?
| Program Evaluation | 1 | 2023 | 349 | 0.050 |
Why?
| Pregnancy | 3 | 2014 | 2584 | 0.050 |
Why?
| Enzyme Inhibitors | 1 | 2023 | 391 | 0.050 |
Why?
| Cyclin-Dependent Kinase 2 | 1 | 2020 | 16 | 0.050 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2020 | 36 | 0.050 |
Why?
| Liver Cirrhosis | 1 | 2023 | 218 | 0.050 |
Why?
| Cytidine Monophosphate | 1 | 2020 | 1 | 0.050 |
Why?
| Curriculum | 1 | 2023 | 404 | 0.050 |
Why?
| Flame Ionization | 1 | 2020 | 3 | 0.050 |
Why?
| Medicine, Traditional | 1 | 2020 | 18 | 0.050 |
Why?
| Mice, Inbred NOD | 1 | 2020 | 96 | 0.040 |
Why?
| Plant Leaves | 1 | 2020 | 43 | 0.040 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2020 | 67 | 0.040 |
Why?
| Mice, SCID | 1 | 2020 | 175 | 0.040 |
Why?
| Aldehydes | 1 | 2020 | 83 | 0.040 |
Why?
| Cytokines | 1 | 2023 | 612 | 0.040 |
Why?
| Genomics | 1 | 2021 | 282 | 0.040 |
Why?
| Lipids | 1 | 2020 | 147 | 0.040 |
Why?
| DNA, Viral | 1 | 2019 | 133 | 0.040 |
Why?
| Sesquiterpenes | 1 | 2020 | 90 | 0.040 |
Why?
| Cell Survival | 1 | 2020 | 598 | 0.040 |
Why?
| Cohort Studies | 1 | 2023 | 1422 | 0.040 |
Why?
| Immunohistochemistry | 1 | 2021 | 971 | 0.040 |
Why?
| Genetic Association Studies | 1 | 2019 | 116 | 0.040 |
Why?
| Inflammation | 1 | 2023 | 604 | 0.040 |
Why?
| CTLA-4 Antigen | 1 | 2018 | 25 | 0.040 |
Why?
| Alcohol Drinking | 1 | 2020 | 223 | 0.040 |
Why?
| Neoplasm Recurrence, Local | 1 | 2021 | 618 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 1 | 2020 | 1374 | 0.040 |
Why?
| Signal Transduction | 1 | 2024 | 1617 | 0.040 |
Why?
| Body Mass Index | 1 | 2020 | 652 | 0.040 |
Why?
| Phenotype | 1 | 2019 | 727 | 0.030 |
Why?
| Smoking | 1 | 2020 | 510 | 0.030 |
Why?
| CD4 Lymphocyte Count | 1 | 2014 | 32 | 0.030 |
Why?
| Aged, 80 and over | 1 | 2022 | 3125 | 0.030 |
Why?
| Opportunistic Infections | 1 | 2014 | 59 | 0.030 |
Why?
| Risk Assessment | 1 | 2019 | 1262 | 0.030 |
Why?
| Reagent Kits, Diagnostic | 1 | 2014 | 18 | 0.030 |
Why?
| Genotyping Techniques | 1 | 2014 | 20 | 0.030 |
Why?
| Hepatitis C Antibodies | 1 | 2014 | 20 | 0.030 |
Why?
| Donor Selection | 1 | 2014 | 12 | 0.030 |
Why?
| Drug Resistance, Bacterial | 1 | 2014 | 71 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2014 | 378 | 0.030 |
Why?
| Weight Gain | 1 | 2014 | 240 | 0.030 |
Why?
| Microbial Sensitivity Tests | 1 | 2014 | 271 | 0.030 |
Why?
| Pregnancy Complications, Parasitic | 1 | 2012 | 4 | 0.030 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 2012 | 19 | 0.030 |
Why?
| Molecular Diagnostic Techniques | 1 | 2013 | 32 | 0.030 |
Why?
| Water | 1 | 2012 | 76 | 0.030 |
Why?
| Disease Progression | 1 | 2014 | 822 | 0.030 |
Why?
| Comorbidity | 1 | 2014 | 618 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2012 | 580 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2014 | 2179 | 0.020 |
Why?
| Treatment Outcome | 1 | 2014 | 5138 | 0.010 |
Why?
| Child | 1 | 2012 | 6824 | 0.010 |
Why?
|
|
Nagalo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|